1. Home
  2. BLRX vs GELS Comparison

BLRX vs GELS Comparison

Compare BLRX & GELS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLRX
  • GELS
  • Stock Information
  • Founded
  • BLRX 2003
  • GELS 2018
  • Country
  • BLRX Israel
  • GELS Australia
  • Employees
  • BLRX N/A
  • GELS N/A
  • Industry
  • BLRX Biotechnology: Pharmaceutical Preparations
  • GELS
  • Sector
  • BLRX Health Care
  • GELS
  • Exchange
  • BLRX Nasdaq
  • GELS NYSE
  • Market Cap
  • BLRX 12.2M
  • GELS 12.6M
  • IPO Year
  • BLRX 2011
  • GELS 2024
  • Fundamental
  • Price
  • BLRX $3.10
  • GELS $1.01
  • Analyst Decision
  • BLRX Buy
  • GELS
  • Analyst Count
  • BLRX 2
  • GELS 0
  • Target Price
  • BLRX $26.00
  • GELS N/A
  • AVG Volume (30 Days)
  • BLRX 26.4K
  • GELS 29.2K
  • Earning Date
  • BLRX 05-27-2025
  • GELS 02-15-2025
  • Dividend Yield
  • BLRX N/A
  • GELS N/A
  • EPS Growth
  • BLRX N/A
  • GELS N/A
  • EPS
  • BLRX N/A
  • GELS N/A
  • Revenue
  • BLRX $28,940,000.00
  • GELS $95,618.00
  • Revenue This Year
  • BLRX N/A
  • GELS N/A
  • Revenue Next Year
  • BLRX N/A
  • GELS N/A
  • P/E Ratio
  • BLRX N/A
  • GELS N/A
  • Revenue Growth
  • BLRX 502.92
  • GELS N/A
  • 52 Week Low
  • BLRX $2.85
  • GELS $0.90
  • 52 Week High
  • BLRX $35.60
  • GELS $5.50
  • Technical
  • Relative Strength Index (RSI)
  • BLRX 41.70
  • GELS N/A
  • Support Level
  • BLRX $3.01
  • GELS N/A
  • Resistance Level
  • BLRX $3.61
  • GELS N/A
  • Average True Range (ATR)
  • BLRX 0.22
  • GELS 0.00
  • MACD
  • BLRX 0.02
  • GELS 0.00
  • Stochastic Oscillator
  • BLRX 32.89
  • GELS 0.00

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

About GELS GELTEQ LIMITED

Gelteq Ltd is a clinical and science-based company that is focused on developing and commercializing white-label gel-based delivery solutions to preserve the simplicity, accessibility and efficacy of oral delivery without the impediments traditionally associated with other oral delivery methods, with prescription drugs, nutraceuticals, pet care, and other products. It is engaged in the development and testing of a gel-based delivery system for humans and pets. Its principal products are edible gels.

Share on Social Networks: